Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?
Keyword(s):
Keyword(s):
2018 ◽
pp. 188-222
Keyword(s):
2015 ◽
Vol 4
◽
pp. 6-21
◽
Keyword(s):
2016 ◽
Vol 9
(7)
◽
pp. 679-693
◽
Keyword(s):